Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014458 | 1.00 | CYP11B2 (0.57) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL1015561 | 0.83 | KDM4E (0.57) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL1015559 | 0.83 | KDM4E (0.57) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL12954964 | 0.83 | KDM4E (0.57) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL13527908 | 0.82 | KDM4E (0.75) | MCHR1KDM4EALDH1A1MAPTGFER | |
| SCHEMBL1014609 | 0.81 | SMN1; SMN2 (0.58) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL1014610 | 0.81 | SMN1; SMN2 (0.58) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL2637151 | 0.81 | CYP11B2 (0.50) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL2637153 | 0.81 | CYP11B2 (0.50) | CYP11B2MCHR1KDM4EALDH1A1MAPT | |
| SCHEMBL24463604 | 0.79 | KDM4E (0.55) | CYP11B2MCHR1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| WO-2008065021-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | GPR119, GIPR, EBP | CYP11B2 301/4885MCHR1 437/4885KDM4E 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.